Axinn Granted Summary Judgment in Delaware Federal Court
June 24, 2014
Law360
A Delaware federal judge on June 24 granted summary judgment to Axinn client Alvogen in a lawsuit brought by Novartis AG over a generic version of the Exelon dementia treatment patch. After the close of fact discovery, Novartis granted a covenant not to sue to Alvogen.
Click here to read about the judgment in Law360’s article.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
Consumer Brands CPG Legal Forum 2026
Speaking Engagement
NBA CLS 39th Annual Corporate Counsel Conference
Sponsorship
Antitrust
New Frontiers of Antitrust – 16th Annual International Conference of Concurrences Review
Speaking Engagement
Antitrust
GCR Live Global: Navigating the Future of Antitrust 2026
Speaking Engagement
Antitrust
Axinn Earns Top Antitrust Rankings Coast to Coast in GCR 100
Awards & Recognitions
Why Should I Care About Property Controls?
Speaking Engagement
Antitrust
What’s the Score, Your Honor? Conversation With Judge Richard Boulware
Podcast
LCA Renaissance Symposium XIX 2025
Speaking Engagement
Antitrust
Stakeholders 25th Annual CYOC Career Development Conference
Sponsorship
Antitrust
Japan Competition Law Update
Axinn Viewpoints
Antitrust
